25th November, 2026

To,
The Manager,
Department of Corporate Services,
BSE Limited
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001
Scrip Code:533573

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.
'Exchange Plaza', Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
NSE Symbol: APLLTD

Dear Sir/Madam,

Sub: Receipt of Establishment Inspection Reports (EIRs) pertaining to the unannounced USFDA inspection conducted at the Company's Bioequivalence Facility, Vadodara, Gujarat, from 31st August, 2026 to 10th September, 2026.

Ref.: Our intimation dated 11th September, 2026 regarding successful completion of the unannounced USFDA on-site inspection at Alembic Pharmaceuticals Limited's Bioequivalence Facility at Vadodara, Gujarat.

With reference to our earlier intimation dated 11th September, 2026, we wish to inform the Stock Exchanges that the U.S. Food and Drug Administration (USFDA) has issued two Establishment Inspection Reports (EIRs) in the names of the respective clinical investigators, indicating the closure of the unannounced inspection conducted from 31st August, 2026 to 10th September, 2026 at the Company's Bioequivalence Facility located at Vadodara, Gujarat.

Kindly take the above information on record.

Thanking you,

Yours faithfully,
For Alembic Pharmaceuticals Limited
CHIRAG K SHUKLA
Digitally signed by CHIRAG K SHUKLA
Date: 2026.11.25 17:06:54 +05'30'
Chirag K. Shukla
Company Secretary